Literature DB >> 15763333

Occult hepatitis B virus infection in a North American community-based population.

Gerald Y Minuk1, Dong-Feng Sun, Julia Uhanova, Manna Zhang, Shauna Caouette, Lindsay E Nicolle, Adam Gutkin, Karen Doucette, Bruce Martin, Antonio Giulivi.   

Abstract

BACKGROUND/AIMS: Occult hepatitis B virus (HBV) infection [HBV-DNA detection in hepatitis B surface antigen (HBsAg)-negative individuals] may cause acute and/or chronic liver disease. The objective of this study was to document the prevalence of occult HBV in an isolated, North American Inuit community.
METHODS: Four hundred and eighty seven HBsAg negative sera (61% of the community population) were available for HBV-DNA testing by real time PCR. Of these, 80 (Group 1) had serologic evidence of resolved HBV infection and 407 (Group 2) were HBV-seronegative.
RESULTS: HBV-DNA was detected in 14/80 (18%) and S-variants in 12/14 (86%) samples from Group 1. In Group 2, HBV-DNA was detected in 33/407 (8.1%) and S-variants in 17/33 (52%). In all cases (Groups 1 and 2) viral loads were low (<10(5) viral copies/ml) and clinical or biochemical features did not distinguish HBV-DNA positive from negative individuals. However, S-variants were more common (P<0.0001) in older age groups.
CONCLUSIONS: The results of this study indicate that in this community-based population; (1) the prevalence of occult HBV infection is 18% in those with serologic evidence of previous HBV infection and 8.1% in HBV seronegative individuals, (2) age, gender and liver biochemistry findings do not identify those with occult HBV and (3) S-variants are present in the majority of individuals with occult HBV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15763333     DOI: 10.1016/j.jhep.2004.11.037

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  31 in total

Review 1.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

2.  Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients.

Authors:  Ozcan Ceneli; Zübeyde Nur Ozkurt; Kadir Acar; Seyyal Rota; Sahika Zeynep Aki; Zeynep-Arzu Yeğin; Münci Yağci; Seren Ozenirler; Gülsan Türköz Sucak
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

3.  Occult hepatitis B infection among blood donors from Yaoundé, Cameroon.

Authors:  Diderot Fopa; Daniel Candotti; Claude T Tagny; Camille Doux; Dora Mbanya; Edward L Murphy; Hany I Kenawy; Farha El Chenawi; Syria Laperche
Journal:  Blood Transfus       Date:  2019-11       Impact factor: 3.443

4.  Prevalence and molecular analysis of occult hepatitis B virus infection isolated in a sample of cryptogenic cirrhosis patients in iran.

Authors:  Fatemeh Akhavan Anvari; Seyed Moayyed Alavian; Mehdi Norouzi; Mostafa Mahabadi; Seyed Mohammad Jazayeri
Journal:  Oman Med J       Date:  2014-03

Review 5.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

6.  Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation.

Authors:  Karen Kwei; Xiaoli Tang; Anna S Lok; Camille Sureau; Tamako Garcia; Jisu Li; Jack Wands; Shuping Tong
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

Review 7.  Current hepatitis B virus infection situation in Indonesia and its genetic diversity.

Authors:  Maria Inge Lusida; Yoshihiko Yano
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

8.  Impact of immune escape mutations and N-linked glycosylation on the secretion of hepatitis B virus virions and subviral particles: Role of the small envelope protein.

Authors:  Xiaohui Bi; Shuping Tong
Journal:  Virology       Date:  2018-03-28       Impact factor: 3.616

9.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

10.  Should hepatitis B serosurveys methodology be reconsidered?

Authors:  Jorge Luis Salinas; Martin Rodriguez
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.